• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Infinity Pharmaceuticals Announces the Date of Its Second Quarter 2022 Financial Results Conference Call and Webcast

    8/2/22 8:25:00 AM ET
    $INFI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INFI alert in real time by email

    Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, August 9th, 2022, at 4:30 pm ET to report its financial results for the second quarter of 2022.

    Conference Call & Webcast Details

    Date:

    Tuesday, August 9th  

    Time:

    4:30 pm Eastern Time

    Webcast:

    https://edge.media-server.com/mmc/p/ci3bx9cc

    Toll Free:

    (800) 715-9871

    International:

    (646) 307-1963

    ID Number:

    303241

    A live webcast of the conference call can be accessed in the Investors/ Media section of Infinity's website at https://www.infi.com/ and will be available on Infinity's website for 30 days following the event.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005258/en/

    Get the next $INFI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INFI

    DatePrice TargetRatingAnalyst
    10/18/2021$9.00Buy
    HC Wainwright & Co.
    8/2/2021$6.00Neutral → Overweight
    JP Morgan
    7/28/2021$4.00 → $14.00Equal-Weight → Overweight
    Wells Fargo
    7/7/2021$7.00Buy
    B. Riley Securities
    More analyst ratings

    $INFI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Perkins Adelene Q converted options into 768,133 shares and sold $28,714 worth of shares (410,196 units at $0.07), increasing direct ownership by 44% to 1,175,291 units

    4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)

    9/12/23 6:20:24 PM ET
    $INFI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Peluso Stephane converted options into 50,000 shares, increasing direct ownership by 1,711% to 37,052 units to cover taxes

    4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)

    8/4/22 6:26:16 PM ET
    $INFI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Evnin Anthony B was granted 46,378 shares, increasing direct ownership by 27% to 215,403 units

    4 - INFINITY PHARMACEUTICALS, INC. (0001113148) (Issuer)

    6/16/22 9:29:24 PM ET
    $INFI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INFI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan

    Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced a series of actions designed to reduce the Company's burn rate and enhance our ability to maximize value of eganelisib, following the termination of its previously announced merger agreement with MEI Pharma, Inc. The Company continues to believe, based on the data generated to date, that eganelisib offers a near-term value creation opportunity that would be attractive to potential third-party acquirers. Infinity has advanced eganelisib toward the init

    7/25/23 4:05:00 PM ET
    $INFI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma

    Eganelisib Remains Primary Value Driver for Infinity Infinity to Explore Strategic Alternatives to Maximize Value for Stockholders Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, announced that it has terminated its previously announced merger agreement providing for the merger with MEI Pharma, Inc. ("MEI"). At a special meeting of MEI stockholders on July 23, 2023, MEI did not obtain MEI stockholder approval for the merger with Infinity, nor could MEI obtain approval for an adjournment of the special meeting. In the process o

    7/24/23 8:30:00 AM ET
    $INFI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction

    MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reminded shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity") in connection with the Company's special meeting on July 23, 2023. MEI issued the following statement: Our shareholders have the opportunity to shape the future of their MEI investment. By voting FOR the Infinity transaction today, you have the opportunity to participate in the upside potential of a combined company with: a diversified therapeutic pipeline; a team that brings clinical development and regulatory expertise; and the capabilities and resources to develop new oncology therapeutics for the benefi

    7/19/23 8:00:00 AM ET
    $INFI
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INFI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on Infinity Pharmaceuticals with a new price target

    HC Wainwright & Co. initiated coverage of Infinity Pharmaceuticals with a rating of Buy and set a new price target of $9.00

    10/18/21 6:27:01 AM ET
    $INFI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Infinity Pharmaceuticals upgraded by JP Morgan with a new price target

    JP Morgan upgraded Infinity Pharmaceuticals from Neutral to Overweight and set a new price target of $6.00

    8/2/21 5:42:58 AM ET
    $INFI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Infinity Pharmaceuticals upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Infinity Pharmaceuticals from Equal-Weight to Overweight and set a new price target of $14.00 from $4.00 previously

    7/28/21 5:37:19 AM ET
    $INFI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INFI
    SEC Filings

    View All

    Infinity Pharmaceuticals Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Leadership Update

    8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)

    9/29/23 4:04:01 PM ET
    $INFI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Infinity Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)

    9/13/23 8:11:15 AM ET
    $INFI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Infinity Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - INFINITY PHARMACEUTICALS, INC. (0001113148) (Filer)

    9/11/23 4:09:04 PM ET
    $INFI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INFI
    Financials

    Live finance-specific insights

    View All

    MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates

    Combination will create a company with a diverse product development pipeline led by a planned new global Phase 2 clinical trial evaluating eganelisib in head and neck squamous cell carcinoma (HNSCC) Projected ~$100M cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months Companies to host conference call and webcast today at 8:00 a.m. ET MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno

    2/23/23 7:00:00 AM ET
    $INFI
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Infinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

    – MARIO-3 Update in Patients with 1L TNBC showing 52% increase in one-year progression free survival rate in ITT patient population compared to Impassion130 benchmark – – Business development discussions advancing with goal of announcing a partnership in Q1 2023 – – Cash runway into 2024 with $47.2 million in cash and cash equivalents at end of Q3 2022– – Investor conference call to be held today at 8:30 AM ET – Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its third quarter 2022 financial results, provi

    11/14/22 7:07:00 AM ET
    $INFI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Infinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and Webcast

    Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Monday, November 14, 2022, at 8:30 AM ET to report its financial results for the third quarter of 2022. To access the conference call, please register at https://register.vevent.com/register/BId44f86e6a2af42faadbb2844131346a8. Upon registering, each participant will be provided with call details and access codes. All participants are encouraged to join 10 minutes prior to the start time. A live webcast of the conference call can be accessed from the Events & Presentations page

    11/7/22 8:25:00 AM ET
    $INFI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INFI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Infinity Pharmaceuticals Inc. (Amendment)

    SC 13G/A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)

    2/14/23 3:59:19 PM ET
    $INFI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Infinity Pharmaceuticals Inc. (Amendment)

    SC 13G/A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)

    2/9/23 11:22:21 AM ET
    $INFI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Infinity Pharmaceuticals Inc. (Amendment)

    SC 13G/A - INFINITY PHARMACEUTICALS, INC. (0001113148) (Subject)

    2/14/22 2:01:09 PM ET
    $INFI
    Biotechnology: Pharmaceutical Preparations
    Health Care